Reading CC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CC free→Reading CC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CC free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-06-12
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been steady. Risk is high, and the sector backdrop is a headwind. Compared with sector peers, the company is below typical. Peer multiples imply a price about 10% below where it trades (it looks expensive on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $22.00. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $22 CC trades at 25× p/e, in line with its 20× p/e peer median. Our $20 fair value reflects that, low confidence. Analysts: $17–$30. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 10% near-term growth, ahead of our forecast of about -3%. This describes what's priced in, not a forecast of the move.
No fragility gates fired. Regime (Crisis) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Materials names rated neutral grew net income 56% of the time over the next year (vs 57% for the rest of the cohort, n=1462).
Over the trailing year it converted -0.81x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
1 material management or governance event in the past 24 months, led by executive changes. Historically, Materials names rated stable grew net income 45% of the time over the next year (vs 58% for the rest of the cohort, n=210).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.63 → $0.42 (-33.5% / 30d). 0 raised, 8 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 56% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$240.
How much price usually moves either way.
On a bad day, this stock has moved -$554.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,978.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'low'.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Hitting this target is important for Chemours' money health and future projects.
Confirms:Free cash flow reported at or above $100M for the full year 2026.
Disproves:Free cash flow reported below $100M for the full year 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CC yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 5, 2026, The Chemours Company (the “Company”) issued a press release regarding its first quarter 2026 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. The Company will post to its investor relations website, investors.chemours.com, an investor presentation by 8:00 a.m. Eastern Daylight Time on Wednesday, May 6, 2026, for its conference call scheduled for that time. The information furnished with this repo…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$17.00 – $30.00 (median $26.50) · 14 analysts · as of 2026-05-13
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Diversified Chemicals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CC Chemours | Below typical Show detailsSector percentile: 9 of 100 | full | high |
CBT Cabot Corp | Above typical Show detailsSector percentile: 99 of 100 | inexpensive | moderate |
ASH Ashland Global | Typical Show detailsSector percentile: 64 of 100 | fair | moderate |
OLN Olin Corporation | Typical Show detailsSector percentile: 61 of 100 | inexpensive | elevated |
HUN Huntsman Corp | Typical Show detailsSector percentile: 62 of 100 | fair | high |
Not investment advice. As of 2026-06-12.
via XLB
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
The company aims to achieve a Free Cash Flow of at least $100 million for the fiscal year 2026.
The company plans to maintain capital expenditures between $275 million and $325 million for 2026.
The company aims for net sales growth of 3% to 5% in 2026 compared to 2025.
Why it matters: If the materials sector shows revenue growth, it could help Chemours improve its performance.
Confirms:Materials sector revenue growth exceeds 1% year over year.
Disproves:Materials sector revenue growth remains below 1% year over year.
Why it matters: This range shows how Chemours is managing its investments amid market challenges.
Confirms one read:Capital spending is expected to be between $275M and $325M for 2026.
Confirms the other:Capital spending is expected to be outside the $275M to $325M range for 2026.
Why it matters: This growth range is key for Chemours to meet its 2026 sales target. It shows if the company is recovering in a tough market.
Confirms:Q2 net sales growth reported between 3% and 5% compared to Q1 2025.
Disproves:Q2 net sales growth falls below 3% year over year.
Why it matters: Earnings results will show if Chemours can improve its financial condition. This is key for investors.
Confirms one read:Earnings report shows revenue growth above 1% year over year.
Confirms the other:Earnings report shows revenue growth below 1% year over year.
The filing is about the approval of a new equity and incentive plan, not a management change.